<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Written Evidence submitted by Professor T H Pennington MB BS, PhD, FRCPath</title></head><body><div><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">evidence </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">submitted by Professor T H Pennington MB BS, PhD, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">FRCPath</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">(AMR0013)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Summary</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">This evidence focuses on the application of next-generation DNA sequencing to </span><span style="font-family:'Times New Roman'; font-size:11pt">the AMR problem</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Whole genome sequencing of clinical isolates of pathogenic bacteria in real time will significantly improve our ability to 1) </span><span style="font-family:'Times New Roman'; font-size:11pt">track their routes of transmission, </span><span style="font-family:'Times New Roman'; font-size:11pt">2) </span><span style="font-family:'Times New Roman'; font-size:11pt">detect new resistant organisms </span><span style="font-family:'Times New Roman'; font-size:11pt">and 3) identify targets for new antibiotics.</span><span style="font-family:'Times New Roman'; font-size:11pt"> I recommend that it should receive designated funding.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">I was Professor of Bacteriology at the University of Aberdeen from 1979 to 2003 and President of the Society for General Microbiology from 2003-2006. I chaired the Public Inquiry into the 2005 South Wales </span><span style="font-family:'Times New Roman'; font-size:11pt">E.coli</span><span style="font-family:'Times New Roman'; font-size:11pt"> O157 outbreak, which published its report in 2009. I was appointed CBE in 2013 for services to microbiology and food hygiene, and am a Fellow of </span><span style="font-family:'Times New Roman'; font-size:11pt">the Royal Society of Edinburgh, the Royal College of Physicians of Edinburgh, and </span><span style="font-family:'Times New Roman'; font-size:11pt">the Academy of Medical Sciences</span><span style="font-family:'Times New Roman'; font-size:11pt">. I am President of MRSA Action UK.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">I have conducted research</span><span style="font-family:'Times New Roman'; font-size:11pt"> on several aspects of antibiotic act</span><span style="font-family:'Times New Roman'; font-size:11pt">ion and resistance</span><span style="font-family:'Times New Roman'; font-size:11pt">, including the inhibition of smallpox replication by rifampicin, MRSA fingerprinting, and the molecular basis of the resistance of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Neisseria</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">meningitidis</span><span style="font-family:'Times New Roman'; font-size:11pt"> to </span><span style="font-family:'Times New Roman'; font-size:11pt">rifampicin</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> A</span><span style="font-family:'Times New Roman'; font-size:11pt"> particular focus of my work</span><span style="font-family:'Times New Roman'; font-size:11pt"> has been</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">the development and application</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">of </span><span style="font-family:'Times New Roman'; font-size:11pt">molecular fingerprinting methods to </span><span style="font-family:'Times New Roman'; font-size:11pt">tra</span><span style="font-family:'Times New Roman'; font-size:11pt">ck the spread of pathogens</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1.</span><span style="font-family:'Times New Roman'; font-size:11pt">Whole genome sequencing on a routine basis of large numbers of clinical isolates of pathogenic bacteria is now possible. </span><span style="font-family:'Times New Roman'; font-size:11pt">In the last decade the </span><span style="font-family:'Times New Roman'; font-size:11pt">cost and turn round time of DNA sequencing has fallen like a stone. In 2001 sequencing a human genome cost $100M. It now costs $8,000. The rate of fall of costs began to outpace Moore</span><span style="font-family:'Times New Roman'; font-size:11pt">’</span><span style="font-family:'Times New Roman'; font-size:11pt">s Law for computers (the number of transistors on an integrated circuit doubles every two years) in January 2008 with the introduc</span><span style="font-family:'Times New Roman'; font-size:11pt">tion of next-</span><span style="font-family:'Times New Roman'; font-size:11pt">generation sequencing methods</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2.The power and utility of next-generation sequencing was illustrated by studies on the </span><span style="font-family:'Times New Roman'; font-size:11pt">enormous outbreak</span><span style="font-family:'Times New Roman'; font-size:11pt"> of bloody diarrhoea and the haemolytic </span><span style="font-family:'Times New Roman'; font-size:11pt">uraemic</span><span style="font-family:'Times New Roman'; font-size:11pt"> syndrome in Germany</span><span style="font-family:'Times New Roman'; font-size:11pt"> (well over 4,000 cases and 50 deaths)</span><span style="font-family:'Times New Roman'; font-size:11pt"> and </span><span style="font-family:'Times New Roman'; font-size:11pt">a smaller one in </span><span style="font-family:'Times New Roman'; font-size:11pt">France </span><span style="font-family:'Times New Roman'; font-size:11pt">caused by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">E.coli</span><span style="font-family:'Times New Roman'; font-size:11pt"> O104:H4 (</span><span style="font-family:'Times New Roman'; font-size:11pt">Grad,YH</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">Lipsitch</span><span style="font-family:'Times New Roman'; font-size:11pt"> M &amp; 32 others (2012) Genomic epidemiology of the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Escherichia coli</span><span style="font-family:'Times New Roman'; font-size:11pt"> O104:H4 outbreaks in Europe, 2011. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Proc </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Natl</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Acad</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Sci</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> USA</span><span style="font-family:'Times New Roman'; font-size:11pt"> 109:3065-3070.</span><span style="font-family:'Times New Roman'; font-size:11pt">) </span><span style="font-family:'Times New Roman'; font-size:11pt">These authors conclude</span><span style="font-family:'Times New Roman'; font-size:11pt">d</span><span style="font-family:'Times New Roman'; font-size:11pt"> ‘this study argues strongly for multiple genome sequences to understand patterns of transmission within an outbreak, Such analyses can already be conducted in a matter of days</span><span style="font-family:'Times New Roman'; font-size:11pt">, and technological advances will only improve our ability to perform them in real time….As this example demonstrates, the results of such analysis, combined with traditional epidemiology, can raise novel epidemiologic hypotheses and questions that are available through sequencing of multiple isolates’.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3. There is still much</span><span style="font-family:'Times New Roman'; font-size:11pt"> uncertainty regarding the routes of transmission of many important pathogens. A good example is </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Staphylococcus </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">aur</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">eus</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Although much progress has been made in reducing the incidence of MRSA infections, this has now levelled off</span><span style="font-family:'Times New Roman'; font-size:11pt">  (the Public Health England Quarterly Analyses of Mandatory </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Staphylococcus </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">aureus</span><span style="font-family:'Times New Roman'; font-size:11pt"> bacteraemia published on September 2013 says for MRSA ‘The total number of MRSA bacteraemia reports has shown a small increase of 6% when compared to the same period last year – from 224 in Q2 2012 to 237 in Q2 2013.’)</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Staphylococcus </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">aureus</span><span style="font-family:'Times New Roman'; font-size:11pt"> ( and </span><span style="font-family:'Times New Roman'; font-size:11pt">coagulase</span><span style="font-family:'Times New Roman'; font-size:11pt"> negative staphylococci) are by far the commonest causes of infections following hip</span><span style="font-family:'Times New Roman'; font-size:11pt"> surgery</span><span style="font-family:'Times New Roman'; font-size:11pt">. It</span><span style="font-family:'Times New Roman'; font-size:11pt"> is not</span><span style="font-family:'Times New Roman'; font-size:11pt"> possible to identify with any degree of certainty either the route of transmission or the source of the infecting organism in </span><span style="font-family:'Times New Roman'; font-size:11pt">many </span><span style="font-family:'Times New Roman'; font-size:11pt">patients infected with these organisms. </span><span style="font-family:'Times New Roman'; font-size:11pt">In my vie</span><span style="font-family:'Times New Roman'; font-size:11pt">w the uncertainty that still exists regarding the source and transmission routes of pathogens</span><span style="font-family:'Times New Roman'; font-size:11pt"> comes from a failure to investigate the epidemiolog</span><span style="font-family:'Times New Roman'; font-size:11pt">y of such cases using modern methods. B</span><span style="font-family:'Times New Roman'; font-size:11pt">y far the most important priority for clinical microbiology is to provide information relevant to the </span><span style="font-family:'Times New Roman'; font-size:11pt">management of the patie</span><span style="font-family:'Times New Roman'; font-size:11pt">nt from whom samples were taken; </span><span style="font-family:'Times New Roman'; font-size:11pt">but </span><span style="font-family:'Times New Roman'; font-size:11pt">it hardly ever goes further</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> An enormous number of isolates of pathogens is made in the NHS every year.</span><span style="font-family:'Times New Roman'; font-size:11pt"> I consider that </span><span style="font-family:'Times New Roman'; font-size:11pt">the application of next-generation sequencing of whole genomes to some of these isolates </span><span style="font-family:'Times New Roman'; font-size:11pt">on a significant scale </span><span style="font-family:'Times New Roman'; font-size:11pt">coupled with the clinical information that accompanies them and traditional epidemiology</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> is likely to</span><span style="font-family:'Times New Roman'; font-size:11pt"> improve our understanding of their sources and routes of transmission</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and the evolution of antibiotic resistance mechanisms and their spread, </span><span style="font-family:'Times New Roman'; font-size:11pt">by orders of magnitude. </span><span style="font-family:'Times New Roman'; font-size:11pt">In turn it is highly likely that such advances will provide evidence that in turn will enhance our ability to detect, understand and control AMR organisms.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">4</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">I consider that th</span><span style="font-family:'Times New Roman'; font-size:11pt">is would make a material</span><span style="font-family:'Times New Roman'; font-size:11pt"> and rapid</span><span style="font-family:'Times New Roman'; font-size:11pt"> contribution to one of the three</span><span style="font-family:'Times New Roman'; font-size:11pt"> strategic aim</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> of t</span><span style="font-family:'Times New Roman'; font-size:11pt">he UK 5 Year Antimicrobial Resistance Strategy 2013-2018</span><span style="font-family:'Times New Roman'; font-size:11pt"> : ‘I</span><span style="font-family:'Times New Roman'; font-size:11pt">mproving the knowledge and understanding of AMR</span><span style="font-family:'Times New Roman'; font-size:11pt">’</span><span style="font-family:'Times New Roman'; font-size:11pt">. This</span><span style="font-family:'Times New Roman'; font-size:11pt"> document mentions whole genome sequencing in </span><span style="font-family:'Times New Roman'; font-size:11pt">para</span><span style="font-family:'Times New Roman'; font-size:11pt"> 4.7, 4.12 and 5.3 and recommends that its development and uptake be promoted by Research Councils, other research funders, and academics.</span><span style="font-family:'Times New Roman'; font-size:11pt"> But funding for it is not identified in the AMR strategy impact assessment. It is possible that some projects using it will be</span><span style="font-family:'Times New Roman'; font-size:11pt"> conducted or supported by the </span><span style="font-family:'Times New Roman'; font-size:11pt">proposed National Institute for Health Research Health Protection Unit on AMR and Health Care Associated Infections.</span><span style="font-family:'Times New Roman'; font-size:11pt"> However, I consider that next-generation whole genome sequencing of bacterial genomes is so likely to deliver benefits regarding AMR</span><span style="font-family:'Times New Roman'; font-size:11pt"> that it should be identified for specific support.</span></p><p style="margin:0pt; text-align:justify"><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p></div></body></html>